We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Critical Path Faces Tension Between Funding and Predictability
Critical Path Faces Tension Between Funding and Predictability
April 7, 2006
As the FDA seeks outside funding to narrow down the 76 projects on its Critical Path opportunities list, some industry sources are calling for reassurance the projects will result in “deliverables” that pass regulatory muster.